CAMBRIDGE, UK I November 11, 2024 I STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it ...
NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria ...
ARCADIA, CA, USA I 11, 2024 I Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback